阳光诺和BTP4507药物临床试验获批

Core Viewpoint - Sunshine Nuohe's subsidiary, Jiangsu Nuohe Bitop, has received approval from the National Medical Products Administration for the clinical trial application of its drug BTP4507, which is aimed at treating primary hypertension patients with poor response to monotherapy [1] Group 1 - The clinical trial approval is for BTP4507, classified as a Class 2 modified new chemical drug [1] - The intended indication for BTP4507 is for the treatment of primary hypertension patients who do not respond well to monotherapy [1]